New York, July 31, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Thrombosis And Hemostasis Biomarkers Market Size, Share & Industry Trends Analysis Report By ...

Clinical Phenotype: Can Each RBD be Characterized in Terms of Typical Bleeding Features? Patients affected by RBDs present with a wide range of clinical phenotypes – being asymptomatic at one end of ...

Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for ...

Professor Krystyna Zawilska passed away on August 23, 2019. She was a distinguished internist and hematologist, and a leading expert on thrombosis and hemostasis in Poland. In the last 12 years, she ...

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects. Now new research by Fox Chase Cancer Center physicians shows ...

High-molecular-weight hydroxyethyl starches (hetastarches) can cause acquired type I von Willebrand's disease. 1 A case has also occurred after treatment with medium-molecular-weight hydroxyethyl ...

For decades hemophilia and allied bleeding disorders caused by inherited deficiency of clotting factors have been considered conditions protecting against thromboembolism (TE). This opinion was coined ...

The global Hemostasis Diagnostics market, valued at approximately USD 6.41 billion in 2022, is projected to grow at a healthy CAGR of more than 8.60% during the forecast period from 2023 to 2030.